The molecular effects of etoposide in haemopoietic cells suggest that mixed lineage leukaemia (MLL) abnormalities can be biomarkers of patient susceptibility to the genotoxic effects of topoisomerase 2 (topo 2) inhibitors. We have prospectively studied treatment-related MLL cleavage and rearrangement in serial samples from 71 children receiving chemotherapy, using Southern blot analysis and panhandle PCR. The results were related to patient demographics, treatment details and outcome. MLL cleavage was identified in six bone marrow samples from five patients 2-10 months after the start of therapy. There was no obvious relationship between the degree of MLL cleavage and cumulative dose or schedule of topo 2 inhibitors. Three children with low percentage (23-30%) cleavage remained well and two were still receiving treatment at study completion. One child with two consecutively positive samples and higher level of MLL cleavage (45-48%) died from treatment-related toxicities and relapsed leukaemia. A patient with haemophagocytic lymphohistiocytosis developed the highest level of MLL cleavage (50%) at 3 months and a treatment-related leukaemia with MLL rearrangement 6 months after the start of treatment. It would appear that some patients are inherently more susceptible to the genotoxic effect of topo 2 inhibitors. The degree and persistence of MLL cleavage may identify patients at risk.
Introduction
Treatment-related leukaemia (TRL) is a serious complication following exposure to topoisomerase 2 (topo 2) inhibitors and carries a poor outcome. [1] [2] [3] [4] [5] [6] There is a risk association with frequent scheduling and high cumulative dosage, but it is still unclear as to why TRL does not affect the majority of patients who have received the same treatment. Furthermore, TRL cases have been described in children treated with apparently safe schedules and low cumulative dosage of topo 2 inhibitors. 7 The direct effect of topo 2 inhibitors in inducing mixed lineage leukaemia (MLL) gene cleavage in vitro, 8, 9 and the frequent findings of MLL rearrangement in these TRLs, 4, 6 suggest that MLL gene abnormalities may be useful in identifying patients susceptible to the genotoxic effects of such therapy and their risk of developing TRL. We attempted to investigate the presence and significance of treatment-related MLL cleavage and rearrangement in vivo.
Patients and methods
Children with malignant disease and haemophagocytic lymphohistiocytosis (HLH) receiving multiagent chemotherapy including etoposide and/or anthracyclines between 1998 and 2000 at the Royal Manchester Children's Hospital were recruited into the study. Following informed parental consent, clinical and treatment details were collected from the case notes. Serial blood and bone marrow samples were obtained and immediately frozen at À201C from the patients at diagnosis, and at various time points during and on completion of treatment.
Genomic DNA was extracted soon after collection and digested with BamH1 restriction enzyme, size fractionated by agarose gel electrophoresis and transferred onto nylon membranes by Southern blotting. Denatured DNA on the nylon membranes was hybridised at 601C with a radiolabelled, 0.74 kb MLL cDNA probe spanning the MLL breakpoint cluster region. The signal radioactivity was detected by real-time autoradiography and quantified using the system software (Packard). The percentage of MLL cleavage was measured as the proportion of cleavage from total MLL BCR signal activity.
BamH1 digested DNA was also used as template for panhandle PCR, as described by Felix and Jones, 10 for the detection of MLL rearrangement.
The presence of MLL cleavage and rearrangement was related to the treatment details, patient clinical features and outcome.
Anonymised cord blood samples from 71 normal term infants, matched for sex and ethnic origin to the patient cohort, were used as controls. Approval was obtained from the local research and ethics committee for this research and for cord blood sampling.
Results

Patient demographics
A total of 71 children (33 females), age 12 months to 15 years, were studied. Most (63) were Caucasians, with one AfroCaribbean, three Asians and three of mixed race. Their diagnoses, clinical features and clinical outcome are summarised in Table 1 .
Treatment for primary disease
The treatment details of children with solid tumours are summarised in Table 2 . Seven children with stage 4 neuroblastoma were treated as per the European Neuroblastoma Study Group (ENSG 5) trial. One patient had progressive disease and further received two courses of CAV (cyclophosphamide, /day for 3 days, 6 weeks apart; B4 -30 mg/m 2 every 3 weeks. Note: All VP16 was administered as an infusion over 4 h. All Dox was administered as an infusion over 6 h, except for B1 (24 h infusion).
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A Ng et al doxorubicin and vincristine), meta-iodobenzylguanidine, irinotecan and oral etoposide.
All three cases of nonmetastatic osteosarcoma received therapy according to the European Osteosarcoma Intergroup Medical Research Council (MRC) BO06 protocol. The child with Ewing's sarcoma was treated on the European Intergroup Cooperative Ewing's Sarcoma Study (EICESS) 92, but her disease progressed after three courses and she received second-line treatment with surgery, etoposide and carboplatin.
Of the two malignant germ cell tumours (GCT), one had a primary pineal tumour and was treated according to the International Society of Paediatric Oncology (SIOP) intracranial GCT protocol. The other patient with sacrococcygeal GCT received treatment on the United Kingdom Childhood Cancer Study Group (UKCCSG) GCT 2 Study.
Two patients with inoperable Wilms' tumour received treatment on regimen 15 (Group C) of the UKCCSG Wilms' tumour 3 Study.
One child with unilateral retinoblastoma had primary enucleation and received chemotherapy according to the UKCCSG adjuvant chemotherapy protocol.
In all, 28 children with acute lymphoblastic leukaemia (ALL) were treated according to the MRC ALL97, HR1/ALL99 protocols and 13 (one with T-cell non-Hodgkin's lymphoma) on the ALL99 protocol (schedules A-C). The change in the UK treatment in 1999 involved different intensification therapy and stratification on the basis of initial response. The patient with B-ALL received treatment according to the LMB96-Group C arm2. The treatment of all 42 children with ALL/NHL is summarised in Table 3a .
All 12 patients with acute myeloid leukaemia (AML) were treated according to the MRC AML12 protocol. One child received a matched unrelated donor bone marrow transplant after second-line therapy with fludarabine, cytarabine and idarubicin. The child with EBV-related HLH was treated according to the HLH94 protocol. His therapy was stopped at week 8 because of good clinical response. However, this child developed a treatment-related AML (t-AML) 6 months after the start of this primary therapy, when he was still in remission for HLH. Information on the primary treatment is summarised in Table 3b .
Demographic of patient samples
A total of 420 patient samples from the 71 patients were studied for MLL gene abnormalities, of which 272 were blood and 148 bone marrow specimens. A total of 338 of these were serial samples (235 blood, 103 bone marrow) obtained from the patient cohort during their treatment. The distribution of these samples is summarised in Table 4 .
On-treatment blood and bone marrow samples were obtained from these patients after they had received a range of cumulative dosages (etoposide 200-3400 mg/m 2 , daunorubicin 50-300 mg/m 2 , doxorubicin 25-450 mg/m 2 , mitozantrone 12-122 mg/m 2 , amsacrine 100-500 mg/m 2 ) and schedules of topo 2 inhibitors (Tables 2 and 3) . Most of these patients had not received very high cumulative dosage of topo 2 inhibitors by the time of sampling, but some children had been given etoposide at twice weekly to 10 day intervals in their primary treatment.
Analysis of MLL abnormalities in patient and control samples
Cleavage of the MLL BCR resulting in two fragments of 6.7 and 1.5 kb was detected in six bone marrow samples obtained from five children during treatment. Four of these patients had a primary diagnosis of ALL and one had HLH (Figure 1a and b) . Apart from translocation t (8;14) and hyperdiploidy in two children with ALL, no other specific primary cytogenetic abnormality was found in the five patients.
The MLL abnormality in these five children was found at different stages of treatment following the administration of topo 2 inhibitors. Cleavage was detected in two children with cALL, one at week 8 and one at week 40, after they had received 500 mg/m 2 etoposide, 90 mg/m 2 daunorubicin and in the latter patient 150 mg/m 2 doxorubicin. MLL cleavage was identified in two consecutive bone marrow samples from one child with T-ALL at weeks 18 and 40 following 90 mg/m 2 daunorubicin, 75-150 mg/m 2 doxorubicin and 500 mg/m 2 etoposide. The same abnormality was found in the bone marrow of a patient with B-ALL after an intensive course of chemotherapy with COPADM 2 including 120 mg/m 2 doxorubicin. All five bone marrow samples with evidence of MLL cleavage were obtained from patients already in remission for their primary leukaemia (morphologically less than 5% blasts). None of these four children had received frequent scheduling (weekly or more frequent) of epipodophyllotoxin, but two had brief periods of weekly anthracyclines by the time of sampling and detection of MLL cleavage. On the contrary, a patient with HLH had received weekly to twice weekly etoposide and developed MLL cleavage in his bone marrow after nine courses of etoposide and a cumulative dose of 1350 mg/m 2 ( Figure 2 ). The amount of MLL cleavage detected in these patients ranged from 23 -to 50% of total MLL BCR.
MLL rearrangement following topo 2 inhibitor therapy was only detected in the bone marrow of the child with HLH using both Southern blot analysis and panhandle PCR at the time of presentation with a t-AML. The former identified two translocation fragments of B5.6 and 18 kb, while panhandle PCR detected the 5.6 kb der 11 product (Figure 3 ). Only the germline 8.3 kb MLL BCR fragment was identified in the diagnostic blood and bone marrow samples of these five patients with MLL cleavage, and all the blood samples obtained from the whole cohort.
Similarly, Southern blot analysis detected only the germline 8.3 kb MLL BCR in all cord blood controls. No MLL rearrangements were found in the cord blood samples using the panhandle PCR.
Outcome of children with topo 2 inhibitor-induced MLL cleavage
A low level of MLL cleavage (23-30%) was transiently detected in the bone marrow of two children with cALL. These two patients are still on treatment and have remained in remission. The only child with B-ALL also developed MLL cleavage at low level (30%) after COPADM 2 chemotherapy, but remains in remission. The patient with T-ALL, who had a higher percentage of MLL cleavage (45, 48%) found in two consecutive bone marrow specimens, continued to develop significant treatmentrelated haematological and neurological toxicities (pancytopenia, sepsis and both peripheral and central neuropathy). He subsequently relapsed and died of his leukaemia and therapy side effects. The patient with HLH developed a much higher percentage of MLL cleavage (50%), compared with the cALL patients. He later developed a monocytic t-AML with t(9;11)(p22;q23) and MLL rearrangement 3 months after the detection of MLL cleavage. The characteristics and outcomes of these five patients are summarised in Table 5 . 
Discussion
MLL cleavage detected in bone marrow DNA following in vivo topo 2 inhibitor treatment was similar in pattern and characteristics (6.7 and 1.5 kb fragments) to that identified in haemopoietic cells exposed to etoposide in vitro. 8 The abnormality was identified in 7% of the patients in the cohort, four had a primary diagnosis of ALL (two common, one T-subtype and one B-subtype) and one child had HLH. It was not found in patients with either solid tumours or AML, most of whom had received more anthracyclines, etoposide and more frequent drug scheduling than those with ALL. These results are consistent with the hypothesis that certain individuals are more susceptible to the genotoxic effects of topo 2 inhibitors. Given the small number of each tumour type, it is impossible to say if patients with solid tumour are less susceptible than those with primary ALL. However, the child with HLH had received more frequent scheduling (but not significantly high cumulative dose) of etoposide, a risk factor known to contribute to the development of t-AML. Further studies would be required to clarify whether patients with any specific primary diagnosis are more susceptible to the genotoxic effect of topo 2 inhibitors.
MLL cleavage was identified only in patient bone marrow specimens following treatment with etoposide or anthracyclines, suggesting that the targets susceptible to this drug-related genotoxic effect are probably dividing haemopoietic progenitor cells in the bone marrow. It also implies that such detection in patients is more reliable if bone marrow material is available. However, there remains a possibility that Southern blot analysis is not sufficiently sensitive to identify very low levels of cleavage that might have been present in the peripheral blood samples.
Of the five patients with MLL cleavage, a low percentage (20-30%) of the abnormality was transiently detected in the bone marrow of two children with cALL, but they remained well following treatment for leukaemia. In comparison, more than 40% MLL cleavage was detected in two consecutive samples from a child with T-ALL prior to his leukaemia relapse and subsequent death. A patient with HLH had developed a higher degree (50%) of MLL cleavage at completion of his treatment with frequent exposure to etoposide and then a t-AML with MLL rearrangement 3 months later. There was no clear relationship between the dosage of topo 2 inhibitors received and the amount of cleavage. None of the ALL patients had received recurrent, frequent scheduling of these inhibitors. MLL cleavage can clearly occur in susceptible patients following relatively low cumulative doses and apparently safe scheduling of topo 2 inhibitor treatment. The data also suggest that the amount and persistence of MLL cleavage may be related to the risk of developing MLL rearrangement and TRL. Analysis of serial samples from more cases of TRL and children who did not develop this complication is needed to verify this potential relationship. It is also required to define the suitable time points for the screening of MLL cleavage.
In contrast to gene cleavage, MLL rearrangement was not detected by Southern blot analysis and panhandle PCR in any serial on-treatment samples in this patient cohort, even those from the patient with HLH who subsequently developed a Figure 2 Southern blot analysis of serial samples from the child with HLH. InstantImager bitmap showing the detection of 32 P-labelled MLL probe hybridisation. MLL cleavage fragment (6.7 kb) was identified in a bone marrow sample 3 months after the start of etoposide therapy and MLL rearrangement (5.6 and 18 kb fragments) were detected 3 months later, at his clinical presentation of t-AML. MLL rearrangement resolved with further chemotherapy, prior to his matched unrelated donor transplant.
Figure 3
Panhandle PCR on the same serial samples from the patient with HLH. Gel doc image showing the panhandle PCR product (5.6 kb) following agarose gel electrophoresis. The product was only detected in the patient's bone marrow DNA 6 months after the start of etoposide therapy. Table 5 Characteristics and outcome of patients with topo 2 inhibitor-induced MLL cleavage Topoisomerase 2 inhibitors induced MLL abnormalities in children A Ng et al t-AML. Treatment-induced MLL rearrangement was only identified in the bone marrow of the HLH patient at the time of diagnosis of the t-AML. Although these results are not consistent with the findings reported by Megonigal et al, 11 they should be compared with caution as different methods and sensitivity of detection were used. The identification of MLL cleavage and rearrangement, at different time points, in the same HLH patient who developed a TRL has demonstrated the progression of one molecular abnormality to another during the development of treatment-related leukaemogenesis. This is also the first time in which MLL cleavage and rearrangement has been identified in the same patient following treatment with etoposide. Although there is now evidence that topo 2 cleaves DNA at targeted topo 2 cleavage sites, especially in the presence of topo 2 inhibitors, 4, [12] [13] [14] and that MLL fusion genes probably result from aberrant DNA repair, the exact molecular mechanism is yet to be defined. 9, [14] [15] [16] [17] [18] Our results suggest that the percentage and pattern of MLL cleavage may serve as potential biomarker of patient susceptibility to the genotoxic effects of topo 2 inhibitor therapy and its role warrants further investigation.
